177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

May 26, 2021

Study Completion Date

June 2, 2022

Conditions
Prostatic Neoplasm
Interventions
DRUG

177Lu-PSMA-R2

radio-ligand therapy

Trial Locations (11)

10029

Mount Sinai Hospital School of Medicine, New York

20892

National Institute of Health, Bethesda

21231

John Hopkins University - Kimmel Comp. Cancer Center, Baltimore

53792

University of Wisconsin / Paul P. Carbone Comp Cancer Center, Madison

70112

Tulane Cancer Center Tulance Cancer, New Orleans

85040

Pheonix Molecular Imaging Center, Phoenix

94158

University of California San Francisco, San Francisco

94305

Stanford University Medical Center, Stanford

06520

Yale New Haven Children Hospital, New Haven

Unknown

Hospital Vall Hebrón, Barcelona

Hospital Universitario 12 de Octubre, Madrid

All Listed Sponsors
lead

Advanced Accelerator Applications

INDUSTRY